 Connection
Elizabeth Pomfret to Xenograft Model Antitumor Assays
This is a "connection" page, showing publications Elizabeth Pomfret has written about Xenograft Model Antitumor Assays.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.119 |
|
|
|
-
Ma J, Wang Z, Mintzlaff D, Zhang H, Ramakrishna R, Davila E, Witkowski MT, Lucia MS, Schwartz MS, Pomfret EA, Mathes DW, Wang Z. Bivalent CD47 immunotoxin for targeted therapy of T-cell acute lymphoblastic leukemia. Blood. 2025 Jan 30; 145(5):508-519.
Score: 0.048
-
Qi Z, Qiu Y, Wang Z, Zhang H, Lu L, Liu Y, Mathes D, Pomfret EA, Gao D, Lu SL, Wang Z. A novel diphtheria toxin-based bivalent human EGF fusion toxin for treatment of head and neck squamous cell carcinoma. Mol Oncol. 2021 04; 15(4):1054-1068.
Score: 0.037
-
Wang H, Wang Z, Zhang H, Qi Z, Johnson AC, Mathes D, Pomfret EA, Rubin E, Huang CA, Wang Z. Bispecific human IL2-CCR4 immunotoxin targets human cutaneous T-cell lymphoma. Mol Oncol. 2020 05; 14(5):991-1000.
Score: 0.034
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|